HIV-DNA vaccination following transfer of a large number of activated T cells enhances immunoresponses against HIV-1

Viral Immunology

Volumn 13, Issue 1, 2000, Pages 3-8

  Hamajima, Kenji ^a   Xin, Ke Qin ^a   Fukushima, Jun ^a,b   Yang, Jun ^a   Honsho, Akiko ^a   Nakazawa, Masatoshi ^a   Yanoma, Syunsuke ^c   Okuda, Kenji ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b AKITA PREFECTURAL UNIVERSITY   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; HOST RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; MOUSE; NONHUMAN; PLASMID; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0034103181     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2000.13.3     Document Type: Article

References (25)

1. Andersen, P.M., F.H. Bach, and A.C. Ochoa. 1988. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma. Cancer Immunol. Immunother. 27:82-88.
2. Bukawa, H., K. Sekigawa, K. Hamajima, J. Fukushima, Y. Yamada, H. Kiyono, and K. Okuda. 1995. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nature Med. 1:681-685.
3. Geppert, T.D., and P.E. Lipsky. 1987. Accessory cell independent proliferation of human T4 cells stimulated by immobilized monoclonal antibodies to CD3. J. Immunol. 138:1660-1666.
4. Grimm, E.A., A. Mazumder, H.Z. Zhang, and S.A. Rosenberg. 1982. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155:1823-1841.
5. Hamajima, K., H. Bukawa, J. Fukushima, S. Kawamoto, T. Kaneko, K-I. Sekigawa, S.-I. Tanaka, M. Tsukuda, and K. Okuda. 1995. A macromolecular multicomponent peptide vaccine prepared using the glutaraldehyde conjugation method with strong immunogenicity for HIV-1. Clin. Immunol. Immunopathol. 77:374-379.
6. Hamajima, K., J. Fukushima, H. Bukawa, T. Kaneko, T. Tsuji, Y. Asakura, S. Sasaki, K.-Q. Xin, and K. Okuda. 1997. Strong augmented effect of IL-12 expression plasmid on the induction of HIV-specific cytotoxic T lymphocyte activity by a peptide vaccine candidate. Clin. Immunol. Immunopathol. 83:179-184.
7. Hamajima, K., S. Sasaki, J. Fukushima, T. Kaneko, K.-Q. Xin, I. Kudoh, and K. Okuda. 1998. Intranasal administration of HIV-DNA vaccine formulated with a polymer, carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response. Clin. Immunol. Immunopathol. 88:205-210.
8. Haynes, B.F., G. Pantaleo, and A.S. Fauci. 1996. Toward an understanding of the correlates of protective immunity to HIV infection. Science 271:324-328.
9. Layton, G.T., S.J. Harris, A.J. Gearing, M. Hill-Perkins, J.S. Cole, J.C. Griffiths, N.R. Burns, A.J. Kingsman, and S.E. Adams. 1993. Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3: Ty-virus-like particles. J. Immunol. 151:1097-1107.
10. Malim, M.H., J. Hauber, R. Fenrick, and B.R. Cullen. 1998. Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature 335:181-183.
11. Nehete, P.N., K.S. Casement, R.B. Arlinghaus, and K.J. Sastry. 1995. Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp120. Cell. Immunol. 160:217-223.
12. Okada, E., S. Sasaki, N. Ishii, I. Aoka, T. Yasuda, K. Nishioka, J. Fukushima, J. Miyazaki, B. Wahren, and K. Okuda. 1997. Intranasal immunization of a DNA vaccine with IL-12 and granulocyte macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell mediated immune responses against HIV-1 antigens. J. Immunol. 159:3638-3647.
13. Okuda, K., S.S. Twinig, C.S. David, and M.Z. Atassi. 1997. Genetic control of immune response to sperm whale myoglobin in mice. J. Immunol. 123:182-188.
14. Okuda, K., N. Ishii, Z. Ikezawa, T. Takahashi, K. Arai, and I. Tadokoro. 1982. Delayed-type hypersensitivity to hen egg-white lysozyme. I. The surface phenotypes of suppressor T cells induced by intravenous injection of lysozyme-modified spleen cells, and their molecular interaction. Microbiol. Immunol. 26:897-911.
15. Okuda, K., H. Bukawa, K. Hamajima, S. Kawamoto, K.-I. Sekigawa, Y. Yamada, S.-I. Tanaka, N. Ishi, I. Aoki, M. Nakamura, H. Yamamoto, B.R. Cullen, and J. Fukushima. 1995. Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. AIDS Res. Hum. Retrov. 11:933-943.
16. Okuda, K., T. Kaneko, T. Yamakawa, S. Tanaka, T. Shigematsu, A. Yamamoto, K. Hamajima, K. Nakajima, and S. Kawamoto. 1993. Strong Immunogenecity of multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection. J. Mol. Recognition 6:101-109.
17. Rosenberg, S.A., M.T. Lotze, L.M. Muul, S. Leitman, A.E. Chang, S.E. Ettinghausen, Y.L. Matory, J.M. Skibber, E. Shiloni, J.T. Vetto, C.A. Seipp, C. Simpson, and C.M. Reichert. 1985. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med 313:1485-1492.
18. Sasaki, S., K. Hamajima, J. Fukushima, A. Ihata, N. Ishii, I. Gorai, F. Hirahara, H. Mohri, and K. Okuda. 1998. Immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid a adjuvat vaccine. Infect. Immun. 66:823-826.
19. Scott, B.J., D.A. Lewinsohn, B.K. Patterson, D. Jiyamapa, J. Krieger, L. Corey, P.D. Greenberg, and S.R. Riddell. 1999. In vivo migration and function of transferred HIV-I-specific cytotoxic T cells. Nature Med. 5:34-41.
20. Sekine, T., H. Shiraiwa, T. Yamazaki, K. Tobisu, and T. Kakizoe. 1993. A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients. Biomed. Pharmacother. 47:73-78.
21. Staats, F.H., W.G. Nichols, and T.J. Palker. 1996. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide TISPI0MN(A). J. Immunol. 157:462-472.
22. Takahashi, H., R.N. Germain, B. Moss, and J.A. Berzofsky. 1990. An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 II-restricted help for itself. J. Exp. Med. 171:571-576.
23. Taniguchi, T., H. Matsui, T. Fujita, C. Takaoka, N. Kashima, R. Yoshimoto, and J. Hamuro. 1992. Structure and expression of a cloned cDNA for human interleukin-2. Biotechnology 24:304-309.
24. Thompson, J.A., D.J. Lee, C.G. Lindgren, L.A. Benz, C. Collins, W.P. Shuman, D. Levitt, and A. Fefer. 1989. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res. 49:235-240.
25. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234:1563-1566.